Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 22247010)

1.

Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform.

Casazza A, Kigel B, Maione F, Capparuccia L, Kessler O, Giraudo E, Mazzone M, Neufeld G, Tamagnone L.

EMBO Mol Med. 2012 Mar;4(3):234-50. doi: 10.1002/emmm.201100205. Epub 2012 Jan 13.

2.

Inhibition of semaphorin as a novel strategy for therapeutic angiogenesis.

Moriya J, Minamino T, Tateno K, Okada S, Uemura A, Shimizu I, Yokoyama M, Nojima A, Okada M, Koga H, Komuro I.

Circ Res. 2010 Feb 5;106(2):391-8. doi: 10.1161/CIRCRESAHA.109.210815. Epub 2009 Nov 25.

3.

Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis.

Christensen C, Ambartsumian N, Gilestro G, Thomsen B, Comoglio P, Tamagnone L, Guldberg P, Lukanidin E.

Cancer Res. 2005 Jul 15;65(14):6167-77.

4.

Phosphatidylinositol-4-phosphate 5-kinase and GEP100/Brag2 protein mediate antiangiogenic signaling by semaphorin 3E-plexin-D1 through Arf6 protein.

Sakurai A, Jian X, Lee CJ, Manavski Y, Chavakis E, Donaldson J, Randazzo PA, Gutkind JS.

J Biol Chem. 2011 Sep 30;286(39):34335-45. doi: 10.1074/jbc.M111.259499. Epub 2011 Jul 27.

5.

Neuronal chemorepellent Semaphorin 3E inhibits human airway smooth muscle cell proliferation and migration.

Movassagh H, Shan L, Halayko AJ, Roth M, Tamm M, Chakir J, Gounni AS.

J Allergy Clin Immunol. 2014 Feb;133(2):560-7. doi: 10.1016/j.jaci.2013.06.011. Epub 2013 Aug 6.

PMID:
23932461
6.

Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice.

Casazza A, Finisguerra V, Capparuccia L, Camperi A, Swiercz JM, Rizzolio S, Rolny C, Christensen C, Bertotti A, Sarotto I, Risio M, Trusolino L, Weitz J, Schneider M, Mazzone M, Comoglio PM, Tamagnone L.

J Clin Invest. 2010 Aug;120(8):2684-98. doi: 10.1172/JCI42118. Epub 2010 Jul 26. Erratum in: J Clin Invest. 2011 Jul 1;121(7):2945. Mazzone, Massimilano [corrected to Mazzone, Massimiliano].

7.

Semaphorin 3d and semaphorin 3e direct endothelial motility through distinct molecular signaling pathways.

Aghajanian H, Choi C, Ho VC, Gupta M, Singh MK, Epstein JA.

J Biol Chem. 2014 Jun 27;289(26):17971-9. doi: 10.1074/jbc.M113.544833. Epub 2014 May 13.

8.

Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression.

Roodink I, Kats G, van Kempen L, Grunberg M, Maass C, Verrijp K, Raats J, Leenders W.

Am J Pathol. 2008 Dec;173(6):1873-81. doi: 10.2353/ajpath.2008.080136. Epub 2008 Oct 30.

9.

Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism.

Kim J, Oh WJ, Gaiano N, Yoshida Y, Gu C.

Genes Dev. 2011 Jul 1;25(13):1399-411. doi: 10.1101/gad.2042011.

10.

Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells.

Kigel B, Varshavsky A, Kessler O, Neufeld G.

PLoS One. 2008 Sep 26;3(9):e3287. doi: 10.1371/journal.pone.0003287.

11.

Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice.

Fukushima Y, Okada M, Kataoka H, Hirashima M, Yoshida Y, Mann F, Gomi F, Nishida K, Nishikawa S, Uemura A.

J Clin Invest. 2011 May;121(5):1974-85. doi: 10.1172/JCI44900. Epub 2011 Apr 18.

12.

Semaphorin-plexin signalling genes associated with human breast tumourigenesis.

Gabrovska PN, Smith RA, Tiang T, Weinstein SR, Haupt LM, Griffiths LR.

Gene. 2011 Dec 10;489(2):63-9. doi: 10.1016/j.gene.2011.08.024. Epub 2011 Sep 2.

PMID:
21925246
13.

An image-based RNAi screen identifies SH3BP1 as a key effector of Semaphorin 3E-PlexinD1 signaling.

Tata A, Stoppel DC, Hong S, Ben-Zvi A, Xie T, Gu C.

J Cell Biol. 2014 May 26;205(4):573-90. doi: 10.1083/jcb.201309004. Epub 2014 May 19.

14.

Sema3E/plexin-D1 mediated epithelial-to-mesenchymal transition in ovarian endometrioid cancer.

Tseng CH, Murray KD, Jou MF, Hsu SM, Cheng HJ, Huang PH.

PLoS One. 2011 Apr 29;6(4):e19396. doi: 10.1371/journal.pone.0019396.

15.

Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer.

Tamagnone L.

Cancer Cell. 2012 Aug 14;22(2):145-52. doi: 10.1016/j.ccr.2012.06.031. Review.

16.

Therapeutic potential of semaphorin 3E for the treatment of choroidal neovascularization.

Suda K, Guo C, Oishi A, Ikeda S, Uemura A, Yoshimura N.

Invest Ophthalmol Vis Sci. 2014 Jul 1;55(8):4700-6. doi: 10.1167/iovs.14-14087.

PMID:
24985470
17.

A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells.

Png KJ, Halberg N, Yoshida M, Tavazoie SF.

Nature. 2011 Dec 14;481(7380):190-4. doi: 10.1038/nature10661.

PMID:
22170610
18.

Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1.

Toyofuku T, Yabuki M, Kamei J, Kamei M, Makino N, Kumanogoh A, Hori M.

EMBO J. 2007 Mar 7;26(5):1373-84. Epub 2007 Feb 22.

19.

Semaphorin 3E, an exception to the rule.

Klagsbrun M, Shimizu A.

J Clin Invest. 2010 Aug;120(8):2658-60. doi: 10.1172/JCI44110. Epub 2010 Jul 26.

20.

Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras.

Sakurai A, Gavard J, Annas-Linhares Y, Basile JR, Amornphimoltham P, Palmby TR, Yagi H, Zhang F, Randazzo PA, Li X, Weigert R, Gutkind JS.

Mol Cell Biol. 2010 Jun;30(12):3086-98. doi: 10.1128/MCB.01652-09. Epub 2010 Apr 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk